SCHEMBL27686

SCHEMBL27686

BrCc1cnc2ccccc2n1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 9/20 0.69
MAPT P10636 2/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HIF1A Q16665 1/20 0.44
KDM4E B2RXH2 2/20 0.43
GPR3 P46089 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
HTT P42858 2/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30518375 1.00 PDE10A (0.69) PDE10AMAPTMEN1KMT2ACYP1A2
SCHEMBL12471341 0.83 PDE10A (0.77) PDE10AMAPTMEN1KMT2A
SCHEMBL12066225 0.82 PDE10A (1.00) PDE10AMAPTMEN1KMT2A
SCHEMBL28165727 0.79 PDE10A (0.44) PDE10AMAPTMEN1KMT2ACYP1A2
SCHEMBL2646721 0.78 PDE10A (0.69) PDE10AMAPTMEN1KMT2ACYP1A2
SCHEMBL5247878 0.78 PDE10A (0.69) PDE10AMAPTMEN1KMT2ACYP1A2
SCHEMBL5527742 0.78 PDE10A (0.69) PDE10AMAPTMEN1KMT2ACYP1A2
SCHEMBL752676 0.78 PDE10A (0.69) PDE10AMAPTMEN1KMT2ACYP1A2
SCHEMBL17179177 0.78 PDE10A (0.69) PDE10AMAPTMEN1KMT2ACYP1A2
SCHEMBL5792272 0.78 PDE10A (0.69) PDE10AMAPTMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104974217-B One class dehydroabietic acid quinoxaline derivant and its preparation method and application 南京林业大学 2017-04-05 CN claimed
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF ANACOR PHARMACEUTICALS INC (US) 2025-10-02 US disclosed
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2025-03-27 US disclosed
EP-4380936-A1 PYRAZOLOPYRIDINONE COMPOUNDS BeiGene, Ltd. (KY) 2024-06-12 EP disclosed
CN-118164962-A Bis 1, 4-dihydropyridine derivative, and preparation method and application thereof 河北科技大学 2024-06-11 CN disclosed
EP-3720438-B1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS AMPLYX PHARMACEUTICALS INC (US) 2023-08-30 EP disclosed
CN-111698989-B Heterocyclic substituted pyridine derivatives as antifungal agents 安普利克斯制药公司 2023-08-01 CN disclosed
WO-2023078273-A1 SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-11 WO disclosed
US-20230132298-A1 OXABOROLE ESTERS AND USES THEREOF ANACOR PHARMACEUTICALS, LLC 2023-04-27 US disclosed
CN-114409657-B 4-aryl (methyl) imidazoline quinoxalinone compound and preparation method and application thereof 湖南科技大学 2023-02-24 CN disclosed
WO-1992014740-A1 QUINOXALINE PHOSPHONO-AMINO ACIDS AMERICAN HOME PRODUCTS CORPORATION (US) 1992-09-03 WO disclosed
WO-1992009934-A1 PHOTOSENSITIVE MATERIALS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1992-06-11 WO disclosed
US-5104892-A N-heteroalkyl substitutes 1-aryloxy-2-propanolamine AMERICAN HOME PRODUCTS CORPORATION (US) 1992-04-14 US disclosed
US-5089499-A Anticarcinogenic agents; thymidylate synthetase inhibitors; antiallergens; psoriasis IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-18 US disclosed
US-5084463-A Cardiovascular disorders AMERICAN HOME PRODUCTS CORPORATION (US) 1992-01-28 US disclosed
WO-1991009023-A1 N-HETEROARALKYL-SUBSTITUTED 1-ARYLOXY-2-PROPANOLAMINE AND PROPYLAMINE DERIVATIVES POSSESSING CLASS III ANTIARRHYTHMIC ACTIVITY AMERICAN HOME PRODUCTS CORPORATION (US) 1991-06-27 WO disclosed
EP-0373891-A2 Anti-tumour agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-06-20 EP disclosed
EP-0016061-A4 ORGANIC HALOGEN COMPOUNDS USED IN DIRECT POSITIVE EMULSIONS. DU PONT (US) 1981-08-27 EP disclosed
EP-0016061-A1 ORGANIC HALOGEN COMPOUNDS USED IN DIRECT POSITIVE EMULSIONS. DU PONT (US) 1980-10-01 EP disclosed
WO-1980000040-A1 ORGANIC HALOGEN COMPOUNDS USED IN DIRECT POSITIVE EMULSIONS DU PONT (US) 1980-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 PDE10A 2172/4885MAPT 1201/4885MEN1 832/4885
US-20250304603-A1 OXABOROLE ESTERS AND USES THEREOF OXA1L, HSD17B12, OXER1 PDE10A 2920/4885MAPT 3102/4885MEN1 3587/4885
US-20230132298-A1 OXABOROLE ESTERS AND USES THEREOF OXA1L, HSD17B12, OXER1 PDE10A 2920/4885MAPT 3102/4885MEN1 3587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.